<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367014</url>
  </required_header>
  <id_info>
    <org_study_id>SPIMM-201</org_study_id>
    <nct_id>NCT02367014</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy</brief_title>
  <acronym>MMPOWER</acronym>
  <official_title>Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study for the Safety, Tolerability, and Efficacy of IV MTP-131 for Mitochondrial Myopathy in Genetically Confirmed Mitochondrial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose,
      placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated
      with genetically confirmed mitochondrial disease to evaluate the safety, tolerability,
      pharmacokinetics (PK), and preliminary efficacy of MTP-131 in this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, randomized, double-blind, placebo-controlled study enrolled 36 subjects
      into 3 cohorts of 12 subjects each to evaluate treatment with 3 ascending doses of
      intravenous elamipretide (0.01, 0.10, and 0.25 mg/kg/hr infused for 2 hours). After each
      cohort, a Safety Monitoring Board (SMB) determined if dose escalation to the next higher dose
      of elamipretide was warranted. Each cohort went through 3 distinct periods: Screening,
      Treatment, and Follow-up.

      The Screening Period started with informed consent and may have lasted up to 40 days. During
      this period, screening procedures to determine subject eligibility for the study occurred,
      including confirmation of disease, which incorporated a committee review of the
      investigator-submitted diagnosis and genetic results. The Treatment Period began on Day 1
      (Visit 2) and lasted for 5 days (until Day 5 [Visit 6]). Within each cohort, 9 subjects were
      randomized to active drug and 3 subjects were randomized to placebo on Day 1 and subjects
      received treatment once a day for 5 consecutive days. Safety, tolerability, and efficacy
      measures were performed at pre-specified times. The Follow-up Period began at the time of
      discharge on Day 5. Subjects returned to the study center for the Follow-up Visit on Day 7
      (+1 day).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)</measure>
    <time_frame>Assessed at Baseline, Day 5 (end-of-treatment visit)</time_frame>
    <description>Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Oxygen Uptake (ml/kg/Min)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ventilatory Efficiency (VE/VCO2 Slope)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pre-exercise Lactate Levels (mg/dL)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Post-exercise Lactate Levels (mg/dL)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Respiratory Exchange Ratio (VCO2/VO2)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Respiratory Rate (Breaths/Min)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Ventilation (L/Min)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Heart Rate (Beats/Min)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Systolic Blood Pressure (mmHg)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Diastolic Blood Pressure (mmHg)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Borg Dyspnea</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VO2 Anaerobic Threshold (mL)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Watts</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Temperature (°C)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG-PR Interval (Msec)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG-QRS Complex (Msec)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG-QT Interval (Msec)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG-QTc Interval (Msec)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.</measure>
    <time_frame>Days 1-5 and Day 7.</time_frame>
    <description>Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non‐specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non‐fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self‐injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatine Phosphokinase (IU/L)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT) (U/L)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST) (U/L)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eosinophils (10^9 Cells/L)</measure>
    <time_frame>Baseline, Day 5</time_frame>
    <description>Change in eosinophils as measured by (10^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Mitochondrial Myopathy</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elamipretide (low dose)</intervention_name>
    <description>elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days</description>
    <arm_group_label>Low Dose</arm_group_label>
    <other_name>MTP-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elamipretide (intermediate dose)</intervention_name>
    <description>elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days</description>
    <arm_group_label>Intermediate dose</arm_group_label>
    <other_name>MTP-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elamipretide (high dose)</intervention_name>
    <description>elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days</description>
    <arm_group_label>High dose</arm_group_label>
    <other_name>MTP-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of mitochondrial disease believed to impair the mitochondrial respiratory
             chain.

          -  Eligibility requires prior genetic confirmation of mitochondrial disease.

          -  Diagnosis of mitochondrial myopathy judged by the Investigators to be due to existing
             mitochondrial disease.

          -  Must be able to complete a Screening Visit 6MWT.

          -  Body mass index (BMI) score &gt;15.0 and &lt;35.0 kg/m2 at Screening Visit.

          -  Women of childbearing potential must agree to use birth control as specified in the
             protocol from the date they sign the ICF until two months after the last dose of study
             drug.

        Exclusion Criteria:

          -  Any prior or current medical condition that, in the judgment of the Investigator,
             would prevent the subject from safely participating in and/or completing all study
             requirements.

          -  Had any exclusionary Newcastle Mitochondrial Disease Adult Scale (NMDAS) scores at
             Screening Visit.

          -  Hospitalized (admitted as in-patient) within 1 month prior to the Baseline Visit.

          -  A history of type 1 diabetes mellitus (T1DM).

          -  Uncontrolled Type 1 (T1DM) or Type 2 diabetes mellitus (T2DM), in the opinion of the
             investigator.

          -  A creatinine clearance &lt;45 mL/min as calculated by the Cockcroft Gault equation.

          -  Requires pacemaker, defibrillator, or has undergone cardiac surgery within 2 years of
             Screening Visit.

          -  QTc elongation defined as a QTc &gt;450 msec in male subjects and &gt;480 msec in female
             subjects.

          -  Uncontrolled hypertension (&gt;160 mmHg systolic or &gt;100 mmHg diastolic) at Screening
             Visit.

          -  History of rhabdomyolysis defined as an acute rise in the serum creatine phosphokinase
             (CPK) value that, in the opinion of the investigator, caused clinically significant
             symptoms.

          -  Serum sodium more than 5 meq/L below the reference lower limit of normal at Screening
             Visit.

          -  Participated in another interventional clinical trial within 3 months of the screening
             visit or is currently enrolled in a non-interventional clinical trial judged by the
             Investigator to be incompatible with the current trial.

               -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburg of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>November 16, 2019</results_first_submitted>
  <results_first_submitted_qc>December 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 27, 2019</results_first_posted>
  <last_update_submitted>December 8, 2019</last_update_submitted>
  <last_update_submitted_qc>December 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitochondrial Myopathy</keyword>
  <keyword>Primary Mitochondrial Disease</keyword>
  <keyword>Bendavia™</keyword>
  <keyword>elamipretide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Mitochondrial Myopathies</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Centers: Akron Children’s Hospital; Massachusetts General Hospital; University of Pittsburgh School of Medicine; University of California, San Diego</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>MTP-131: MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Intermediate Dose</title>
          <description>MTP-131: MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="P3">
          <title>High Dose</title>
          <description>MTP-131: MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose</title>
          <description>MTP-131: MTP-131 (low dose) administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Intermediate Dose</title>
          <description>MTP-131: MTP-131 (intermediate dose) administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="B3">
          <title>High Dose</title>
          <description>MTP-131: MTP-131 (high dose) administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="11.32"/>
                    <measurement group_id="B2" value="45.0" spread="14.09"/>
                    <measurement group_id="B3" value="42.3" spread="16.84"/>
                    <measurement group_id="B4" value="41.9" spread="15.83"/>
                    <measurement group_id="B5" value="42.5" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)</title>
        <description>Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Assessed at Baseline, Day 5 (end-of-treatment visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)</title>
          <description>Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="-72" upper_limit="86"/>
                    <measurement group_id="O2" value="36.5" lower_limit="-20" upper_limit="107"/>
                    <measurement group_id="O3" value="64.5" lower_limit="4" upper_limit="133"/>
                    <measurement group_id="O4" value="20.4" lower_limit="-37" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maximum Oxygen Uptake (ml/kg/Min)</title>
        <description>Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>All participants for whom maximum oxygen uptake was measured at baseline and Day 5</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum Oxygen Uptake (ml/kg/Min)</title>
          <description>Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>All participants for whom maximum oxygen uptake was measured at baseline and Day 5</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="2.617"/>
                    <measurement group_id="O2" value="2.36" spread="2.714"/>
                    <measurement group_id="O3" value="0.64" spread="3.121"/>
                    <measurement group_id="O4" value="2.14" spread="3.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ventilatory Efficiency (VE/VCO2 Slope)</title>
        <description>Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>All participants for whom VE/VCO2 slope measurements were recorded at Baseline and Day 5</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ventilatory Efficiency (VE/VCO2 Slope)</title>
          <description>Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>All participants for whom VE/VCO2 slope measurements were recorded at Baseline and Day 5</population>
          <units>VE/VCO2 slope</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.749" spread="2.9412"/>
                    <measurement group_id="O2" value="-0.671" spread="5.4024"/>
                    <measurement group_id="O3" value="-1.681" spread="3.2834"/>
                    <measurement group_id="O4" value="-1.375" spread="5.5801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)</title>
        <description>Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>All participants for whom aerobic efficiency measurements were recorded at Baseline and Day 5</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)</title>
          <description>Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>All participants for whom aerobic efficiency measurements were recorded at Baseline and Day 5</population>
          <units>ΔO2 consumption/Δwork ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.234" spread="4.3414"/>
                    <measurement group_id="O2" value="0.643" spread="2.7507"/>
                    <measurement group_id="O3" value="-0.214" spread="1.9727"/>
                    <measurement group_id="O4" value="0.738" spread="3.5959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)</title>
        <description>Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>All participants for whom oxygen utilization measurements were recorded at Baseline and Day 5</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)</title>
          <description>Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>All participants for whom oxygen utilization measurements were recorded at Baseline and Day 5</population>
          <units>ΔVO2/ΔlogVE ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-118.87" spread="229.105"/>
                    <measurement group_id="O2" value="184.99" spread="410.093"/>
                    <measurement group_id="O3" value="90.13" spread="116.281"/>
                    <measurement group_id="O4" value="166.50" spread="479.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)</title>
        <description>Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom oxygen uptake kinetics was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)</title>
          <description>Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom oxygen uptake kinetics was measured</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="11.402"/>
                    <measurement group_id="O2" value="-2.49" spread="26.830"/>
                    <measurement group_id="O3" value="-9.75" spread="26.288"/>
                    <measurement group_id="O4" value="-7.47" spread="14.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pre-exercise Lactate Levels (mg/dL)</title>
        <description>Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom pre-exercise lactate levels were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pre-exercise Lactate Levels (mg/dL)</title>
          <description>Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom pre-exercise lactate levels were measured</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="9.00"/>
                    <measurement group_id="O2" value="13.8" spread="18.30"/>
                    <measurement group_id="O3" value="0.4" spread="10.25"/>
                    <measurement group_id="O4" value="4.4" spread="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Post-exercise Lactate Levels (mg/dL)</title>
        <description>Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom post- exercise lactate levels were measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post-exercise Lactate Levels (mg/dL)</title>
          <description>Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom post- exercise lactate levels were measured</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="11.87"/>
                    <measurement group_id="O2" value="10.6" spread="42.93"/>
                    <measurement group_id="O3" value="4.3" spread="22.10"/>
                    <measurement group_id="O4" value="8.4" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Respiratory Exchange Ratio (VCO2/VO2)</title>
        <description>Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak respiratory exchange ratio was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Respiratory Exchange Ratio (VCO2/VO2)</title>
          <description>Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak respiratory exchange ratio was measured.</population>
          <units>VCO2/VO2 ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.109" spread="0.0741"/>
                    <measurement group_id="O2" value="0.114" spread="0.1803"/>
                    <measurement group_id="O3" value="0.010" spread="0.0561"/>
                    <measurement group_id="O4" value="0.133" spread="0.1297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Respiratory Rate (Breaths/Min)</title>
        <description>Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak respiratory rate was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Respiratory Rate (Breaths/Min)</title>
          <description>Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak respiratory rate was measured</population>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="6.54"/>
                    <measurement group_id="O2" value="-0.7" spread="5.72"/>
                    <measurement group_id="O3" value="0.9" spread="6.24"/>
                    <measurement group_id="O4" value="8.2" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Ventilation (L/Min)</title>
        <description>Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak ventilation was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Ventilation (L/Min)</title>
          <description>Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak ventilation was measured.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="8.692"/>
                    <measurement group_id="O2" value="8.87" spread="7.975"/>
                    <measurement group_id="O3" value="2.49" spread="8.303"/>
                    <measurement group_id="O4" value="8.47" spread="8.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Heart Rate (Beats/Min)</title>
        <description>Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak heart rate was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Heart Rate (Beats/Min)</title>
          <description>Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak heart rate was measured</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="11.15"/>
                    <measurement group_id="O2" value="16.7" spread="13.02"/>
                    <measurement group_id="O3" value="4.5" spread="9.58"/>
                    <measurement group_id="O4" value="3.8" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin)</title>
        <description>Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak oxygen saturation was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin)</title>
          <description>Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak oxygen saturation was measured.</population>
          <units>percentage of O2-saturated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.69"/>
                    <measurement group_id="O2" value="0.1" spread="1.07"/>
                    <measurement group_id="O3" value="0.6" spread="0.74"/>
                    <measurement group_id="O4" value="0.3" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Systolic Blood Pressure (mmHg)</title>
        <description>Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak systolic blood pressure was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Systolic Blood Pressure (mmHg)</title>
          <description>Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak systolic blood pressure was measured.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="21.00"/>
                    <measurement group_id="O2" value="-1.5" spread="36.47"/>
                    <measurement group_id="O3" value="16.0" spread="12.71"/>
                    <measurement group_id="O4" value="-2.7" spread="21.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Diastolic Blood Pressure (mmHg)</title>
        <description>Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak diastolic blood pressure was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Diastolic Blood Pressure (mmHg)</title>
          <description>Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak diastolic blood pressure was measured</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="12.67"/>
                    <measurement group_id="O2" value="-1.4" spread="11.13"/>
                    <measurement group_id="O3" value="-2.5" spread="9.07"/>
                    <measurement group_id="O4" value="-6.6" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Borg Dyspnea</title>
        <description>Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom peak Borg dyspnea was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Borg Dyspnea</title>
          <description>Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom peak Borg dyspnea was measured.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="2.00"/>
                    <measurement group_id="O2" value="-2.2" spread="2.23"/>
                    <measurement group_id="O3" value="-1.4" spread="1.30"/>
                    <measurement group_id="O4" value="-0.4" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VO2 Anaerobic Threshold (mL)</title>
        <description>Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom VO2 was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VO2 Anaerobic Threshold (mL)</title>
          <description>Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom VO2 was measured.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" spread="83.93"/>
                    <measurement group_id="O2" value="10.8" spread="80.35"/>
                    <measurement group_id="O3" value="1.6" spread="42.17"/>
                    <measurement group_id="O4" value="42.0" spread="51.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Watts</title>
        <description>Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom watts was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Watts</title>
          <description>Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom watts was measured</population>
          <units>watts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="14.15"/>
                    <measurement group_id="O2" value="13.9" spread="12.48"/>
                    <measurement group_id="O3" value="5.4" spread="10.03"/>
                    <measurement group_id="O4" value="4.4" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Temperature (°C)</title>
        <description>Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom temperature was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Temperature (°C)</title>
          <description>Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom temperature was measured</population>
          <units>°C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.54"/>
                    <measurement group_id="O2" value="0.2" spread="0.42"/>
                    <measurement group_id="O3" value="0.1" spread="0.28"/>
                    <measurement group_id="O4" value="0.0" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG-PR Interval (Msec)</title>
        <description>Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom PR interval was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG-PR Interval (Msec)</title>
          <description>Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom PR interval was measured</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="7.77"/>
                    <measurement group_id="O2" value="8.3" spread="7.05"/>
                    <measurement group_id="O3" value="9.1" spread="9.55"/>
                    <measurement group_id="O4" value="-1.6" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG-QRS Complex (Msec)</title>
        <description>Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom QRS complex was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG-QRS Complex (Msec)</title>
          <description>Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom QRS complex was measured</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="7.14"/>
                    <measurement group_id="O2" value="2.3" spread="6.56"/>
                    <measurement group_id="O3" value="-2.2" spread="8.86"/>
                    <measurement group_id="O4" value="0.8" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG-QT Interval (Msec)</title>
        <description>Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom QT interval was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG-QT Interval (Msec)</title>
          <description>Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom QT interval was measured</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="30.53"/>
                    <measurement group_id="O2" value="-4.8" spread="12.94"/>
                    <measurement group_id="O3" value="-16.7" spread="81.02"/>
                    <measurement group_id="O4" value="-1.3" spread="18.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG-QTc Interval (Msec)</title>
        <description>Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom QTc interval was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG-QTc Interval (Msec)</title>
          <description>Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom QTc interval was measured</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="20.17"/>
                    <measurement group_id="O2" value="1.3" spread="20.24"/>
                    <measurement group_id="O3" value="-23.2" spread="77.53"/>
                    <measurement group_id="O4" value="6.7" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.</title>
        <description>Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non‐specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non‐fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self‐injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.</description>
        <time_frame>Days 1-5 and Day 7.</time_frame>
        <population>Participants for whom CSSR was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.</title>
          <description>Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non‐specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non‐fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self‐injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.</description>
          <population>Participants for whom CSSR was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatine Phosphokinase (IU/L)</title>
        <description>Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom creatine phosphokinase was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatine Phosphokinase (IU/L)</title>
          <description>Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom creatine phosphokinase was measured</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" spread="25.10"/>
                    <measurement group_id="O2" value="-161.7" spread="176.49"/>
                    <measurement group_id="O3" value="-101.2" spread="149.07"/>
                    <measurement group_id="O4" value="-154.9" spread="232.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT) (U/L)</title>
        <description>Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom Alanine aminotransferase was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT) (U/L)</title>
          <description>Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom Alanine aminotransferase was measured</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="42.24"/>
                    <measurement group_id="O2" value="-3.0" spread="4.92"/>
                    <measurement group_id="O3" value="-5.3" spread="3.28"/>
                    <measurement group_id="O4" value="1.1" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aspartate Aminotransferase (AST) (U/L)</title>
        <description>Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom aspartate aminotransferase was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aspartate Aminotransferase (AST) (U/L)</title>
          <description>Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom aspartate aminotransferase was measured</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="9.93"/>
                    <measurement group_id="O2" value="-2.2" spread="10.38"/>
                    <measurement group_id="O3" value="-12.6" spread="18.08"/>
                    <measurement group_id="O4" value="-4.4" spread="13.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Eosinophils (10^9 Cells/L)</title>
        <description>Change in eosinophils as measured by (10^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants for whom eosinophils was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eosinophils (10^9 Cells/L)</title>
          <description>Change in eosinophils as measured by (10^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).</description>
          <population>Participants for whom eosinophils was measured</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.073"/>
                    <measurement group_id="O2" value="0.08" spread="0.097"/>
                    <measurement group_id="O3" value="-0.01" spread="0.064"/>
                    <measurement group_id="O4" value="0.04" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose</title>
          <description>MTP-131 (low dose) 0.01 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Intermediate Dose</title>
          <description>MTP-131 (intermediate dose) 0.10 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="E3">
          <title>High Dose</title>
          <description>MTP-131 (high dose) 0.25 mg/kg/hour administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhydrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>CPET was not performed on all subjects.Sensitivity analysis on change from Baseline in pre-and post-exercise lactate levels was not completed.Data from study sites were combined for efficacy and safety analyses.No site- effect analysis was performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jim Carr PharmD Chief Clinical Development Officer</name_or_title>
      <organization>Stealth BioTherapeutics Inc.</organization>
      <phone>617-600-6888</phone>
      <email>jim.carr@stealthbt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

